BIOCAPAN · Project

Implantable Capsule That Frees Diabetics from Daily Insulin Injections for 5 Years

healthTestedTRL 5

Imagine you could put tiny protective bubbles around insulin-producing cells and implant them in a diabetic patient — so their body starts regulating blood sugar on its own, no daily injections needed. The catch has always been that the body attacks these foreign cells, requiring harsh immune-suppressing drugs, or the capsules fail within 2 years. BIOCAPAN designed a smarter capsule that feeds oxygen to the cells inside, prevents scar tissue from blocking them, and calms down the immune system locally — aiming to keep patients injection-free for 5 years without immunosuppressants.

By the numbers

5 years

Target duration of insulin injection-free treatment without immunosuppressants

2 years

Current maximum glycaemia regulation with encapsulated approach

EUR 7,998,875

EU contribution to the project

10 partners

Consortium size across 6 countries

1 in 6

Proportion of Type II diabetes patients requiring insulin who could benefit

The business problem

What needed solving

Millions of diabetes patients depend on daily insulin injections, facing constant self-monitoring and long-term complications. Islet cell transplantation could free them from injections, but current approaches either require lifelong immunosuppressant drugs (with serious side effects) or fail within 2 years due to capsule degradation and immune rejection. The medical device and pharma industries need a durable, immunosuppression-free encapsulation solution to unlock the cell therapy market for diabetes.

The solution

What was built

BIOCAPAN built a demonstrator of a GMP-grade bioactive microcapsule system with integrated oxygenation, anti-fibrotic coating, and local immune modulation — along with a microfluidic manufacturing platform for standardized encapsulation of pancreatic islets. A complete ATMP regulatory protocol was also established for the path to clinical trials.

Audience

Who needs this

Medical device companies developing implantable cell therapy delivery systemsPharmaceutical companies with diabetes or ATMP pipelinesMicrofluidics and bioprocessing equipment manufacturersDiabetes care companies seeking next-generation treatments beyond insulin pumpsRegenerative medicine startups working on cell encapsulation

Business applications

Who can put this to work

Medical device manufacturing

enterprise

Target: Companies producing implantable drug delivery devices or encapsulation systems

If you are a medical device company struggling with biocompatibility and longevity of implantable cell therapies — this project developed a GMP-grade bioactive microcapsule with built-in oxygenation and immune modulation that targets 5 years of functional life, up from the current 2-year maximum. The microfluidic encapsulation platform was designed for standardized, reproducible manufacturing at GMP grade.

Pharmaceutical and cell therapy

enterprise

Target: Pharma companies developing advanced therapy medicinal products (ATMPs) for diabetes

If you are a pharma company investing in cell-based diabetes therapies but hitting walls with immunosuppression requirements — BIOCAPAN built a complete Advanced Therapy Medicinal Products regulatory protocol and achieved preclinical validation. The system eliminates the need for lifelong immunosuppressants, which is a major barrier to patient adoption and market scale for islet transplantation therapies.

Microfluidics and bioprocessing equipment

mid-size

Target: Companies manufacturing microfluidic platforms or cell processing equipment

If you are a bioprocessing equipment maker looking for high-value applications — this project developed a GMP-grade microfluidic microencapsulation platform that can protect freshly harvested pancreatic islets quickly in a standardized and reproducible way. The platform addresses a growing market as cell therapies move toward clinical deployment, with the EUR 7,998,875 project validating the manufacturing approach.

Frequently asked

Quick answers

What would it cost to license or adopt this technology?

The project was funded with EUR 7,998,875 in EU contribution across 10 partners over 4 years. Licensing terms would need to be negotiated with the coordinator (CEA, France). Given the GMP-grade development and ATMP regulatory groundwork already completed, early licensing could reduce development costs significantly for adopters.

Can the encapsulation platform scale to industrial production?

The project specifically developed a GMP-grade microfluidic microencapsulation platform designed for standardized and reproducible manufacturing. GMP compliance means the process was built with industrial-scale production and regulatory approval in mind from the start.

What is the IP situation and how can I license this?

The consortium includes 10 partners across 6 countries (BE, DE, ES, FR, NO, US) with 2 industry partners and 1 SME. IP is likely shared among consortium members per EU Horizon 2020 rules. Contact the coordinator CEA (Commissariat à l'énergie atomique et aux énergies alternatives) in France for licensing discussions.

What regulatory pathway has been established?

BIOCAPAN established a complete protocol in accordance with the Advanced Therapy Medicinal Products (ATMP) Regulation, with the goal of starting clinical trials within one year after the project ended (September 2019). This regulatory groundwork is valuable for any company entering the cell therapy space.

How does this compare to existing diabetes treatments?

Current encapsulated islet approaches achieve a maximum of 2 years of glycaemia regulation. BIOCAPAN targets 5 years of insulin injection-free treatment without immunosuppressants. This addresses all Type I and approximately one in six Type II diabetes patients who require insulin.

What was actually demonstrated and validated?

The project produced a demonstrator of the complete BIOCAPAN system and pursued full preclinical validation. The system includes bioactive microcapsules with in situ oxygenation, anti-fibrotic features, extracellular matrix reconstruction, and immune-system modulation capabilities.

Consortium

Who built it

The BIOCAPAN consortium brings together 10 partners from 6 countries (Belgium, Germany, Spain, France, Norway, and the United States), led by CEA — one of Europe's largest public research organizations. The mix includes 4 universities, 2 industry partners (20% industry ratio), 1 research institute, and 1 SME. The transatlantic presence (including a US partner) signals global ambition and access to both EU and US regulatory pathways. With EUR 7,998,875 in EU funding, this was a substantial investment in moving cell therapy from lab to clinic. The relatively low industry ratio (20%) reflects the early-stage nature of the technology, but the presence of industrial partners and an SME indicates commercial intent.

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESCoordinator · FR
ETABLISSEMENT FRANCAIS DU SANGparticipant · FR
NANOIMMUNOTECH SLparticipant · ES
EUROPEAN RESEARCH SERVICES GMBHparticipant · DE
UNIVERSITE CATHOLIQUE DE LOUVAINparticipant · BE
UNIVERSITE GRENOBLE ALPESparticipant · FR
CHARITE - UNIVERSITAETSMEDIZIN BERLINparticipant · DE
CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLEthirdparty · FR

How to reach the team

CEA (Commissariat à l'énergie atomique et aux énergies alternatives), France — a major French public research organization. Contact through their technology transfer office.

Order a report on this consortium See COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES profile →

Next steps

Talk to the team behind this work.

Want an introduction to the BIOCAPAN team to discuss licensing the microcapsule technology or the microfluidic encapsulation platform? SciTransfer can arrange a direct conversation with the right people.

Order a report on this topic More in Health & Biomedical